AstraZeneca is seeking U.S. approval for its new COVID treatment.
It's asked for emergency authorisation from the Food and Drug Administration.
That's according to a statement from the UK firm.
It concerns an antibody therapy dubbed AZD7442.
AstraZeneca says a late-stage trial shows it reduces the chances of developing COVID-19 symptoms by 77%.
It says the treatment could help people who don't develop a strong immune response after vaccination.
Regular shots require a healthy immune system to develop antibodies in response, while the new treatment contains lab-made antibodies.
U.S. approval would be a big win for the company.
Its widely used shot still hasn't been approved for use there.
AstraZeneca says talks regarding supply of the new treatment are ongoing with the U.S. and other countries.